No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRIX240621C15000
- 1.90
- +0.35+22.58%
15min DelayTrading Jun 12 09:51 ET
2.00High1.90Low
2.00Open1.55Pre Close11 Volume35 Open Interest15.00Strike Price2.10KTurnover168.47%IV0.54%PremiumJun 21, 2024Expiry Date1.81Intrinsic Value100Multiplier9DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type0.7157Delta0.0738Gamma5.95Leverage Ratio-0.0847Theta0.0024Rho4.26Eff Leverage0.0093Vega
Intraday
- 5D
- 1D
News
Nurix Therapeutics Files for Mixed Shelf Securities Offering
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $20
Barclays analyst Peter Lawson maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 41.8% and a
Express News | Nurix Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $23
RBC Capital analyst Gregory Renza maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 45.4% a
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data From the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer
There's Reason For Concern Over Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Massive 28% Price Jump
Nurix Therapeutics, Inc. (NASDAQ:NRIX) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. The last 30 days bring
Comments
$Nurix Therapeutics(NRIX.US$ Nurix Therapeutics Inc - Commenced an Underwritten Public Offering of $125 Mln of Its Common Stock
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Investors may believe the company's poor revenue performance won't improve, causing a low P/S ratio. The company's future revenue growth is expected to be weaker than the industry average, causing discomfort among shareholders.
1
Investors remain skeptical of Nurix Therapeutics' future despite strong performance, with its forecasted growth rate much lower than the industry's 235%. Current P/S ratio hints that expected growth may not justify a higher P/S, needing a turnaround to satisfy investor sentiment.
Read more